Portal de recerca
ESTUDIO DE FASE I/II DE CP-751,871 EN PACIENTES CON TUMORES DE LA FAMILIA DE SARCOMAS DE EWING RECURRENTES Y/O REFRACTARIOS.
Dades bàsiques
- Protocol:
- A4021020
- EURDRACT:
- 2007-004486-17
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2008
- Any de finalització:
- 2012
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
Advances in emerging drugs for the treatment of neuroblastoma
Berlanga, P, Cañete A, Castela, V
Review. 10.1080/14728214.2017.1294159. 2017
Analysis of Biological Prognostic Factors Using Tissue Microarrays in Neuroblastic Tumors
Piqueras, Marta; (...); Noguera, Rosa
Article. 10.1002/pbc.21833. 2009
Anthracycline mediated cardiotoxicity: Detection of miRNA based early biomarkers for the prediction of myocardial injury. Hecatos study
Coloma, C. Salvador; (...); Santaballa, A.
Meeting Abstract. 10.1093/annonc/mdw365.69. 2016
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ladenstein, R; (...); SIOP Europe Neuroblastoma Group (SIOPEN)
Article. 10.1016/S1470-2045(17)30070-0. 2017
Can We Identify Chemotherapy-Related Toxicity in Children with Cancer Through Automatized Integration of Healthcare Information Systems?
Berlanga, P; (...); Canete, A
Meeting Abstract. 2017
Cancer in children and adolescents in Spain: incidence, treatment setting and provider specialty
Berlanga, P.; (...); Castel, V.
Article. 10.1007/s12094-015-1330-y. 2016
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
Berlanga, P; (...); Ladenstein, R
Article. 10.1016/j.ejca.2020.10.020. 2021
Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
J Ribelles A; (...); Castel V
Article. 10.1038/s41598-019-50327-5. 2019
Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors
Berbegall, AP; (...); Noguera, R
Article. 10.1038/onc.2015.200. 2016
Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition
Sanmartin, E; (...); Font de Mora J
Article. 10.1158/1078-0432.CCR-17-0593. 2017
Distribution of segmental chromosomal alterations in neuroblastoma.
Juan Ribelles A; (...); Castel V
Article. 10.1007/s12094-020-02497-2. 2020
El nuevo reto en oncologia: la secuenciacion NGS y su aplicacion a la medicina de precision.
Calabria I; (...); Castel V
Article. 10.1016/j.anpedi.2016.05.006. 2016
Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients.
Grau E; (...); Castel V
Article. 10.1007/s00432-010-0796-9. 2010
Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas
Trinidad, Eva Maria; (...); de Mora, Jaime Font
Article. 10.3389/fonc.2023.1037342. 2023
Evaluation of chimerism by quantitative PCR analysis of DNA polymorphism after allogeneic hematopoietic stem cell transplantation in a pediatric population with malignancies
Bautista, F.; (...); Verdeguer, A.
Article. 10.1111/j.1399-3046.2010.01416.x. 2011
Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1
Rubie, Herve; (...); Michon, Jean
Article. 10.1200/JCO.2010.29.5196. 2011
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Bellini, Angela; (...); Schleiermacher, Gudrun
Article. 10.1200/JCO.21.00086. 2021
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care.
Gargallo P; (...); Cañete A
Article. 10.3390/cancers13215339. 2021
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition
Gargallo, Pablo; (...); Font de Mora, Jaime
Article. 10.1038/s41431-022-01105-x. 2022
HEALTH STATUS AND QUALITY OF LIFE IN A COHORT OF PEDIATRIC CANCER SURVIVORS: PRELIMINARY ANALYSIS OF HUI3 IN THIS POPULATION
Berlanga, Pablo; (...); Castel, Victoria
Article. 2010
HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONAL OUTCOMES OF CHILDREN/ADOLESCENT SURVIVORS OF MALIGNANT BONE TUMORS
Berlanga, P.; (...); Castel, V.
Article. 2014
Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease.
Grau E; (...); Castel V
Article. 10.1002/mc.20700. 2011
Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma
Torres-Vega E; (...); Bataller L
Article. 10.1016/j.jneuroim.2016.05.015. 2016
Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
Coronado, Esther; (...); Font de Mora, Jaime
Article. 10.1002/1878-0261.12868. 2021
Landscape of early clinical trials for childhood and adolescence cancer in Spain
Bautista F; (...); Moreno L
Article. 10.1007/s12094-015-1421-9. 2016
Li-Fraumeni syndrome heterogeneity.
Gargallo P; (...); Cañete A
Review. 10.1007/s12094-019-02236-2. 2020
Liquid Biopsies of Patients with HIGH-RISK Neuroblastoma Disclose Exosomal miRNA Modulation after the Induction Therapy
Morini, M; (...); Varesio, L
Meeting Abstract. 2017
Liquid Biopsy Micro-RNA Profiling in Meduloblastoma
Yanez, Y; (...); Canete, A
Meeting Abstract. 2018
Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA.
Trinidad EM; (...); Font de Mora J
Article. 10.1093/bib/bbac575. 2023
MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.
Grau E; (...); Castel V
Article. 10.1007/s00432-008-0484-1. 2009
Metaiodobenzylguanidine and Neuroblastoma
Balaguer, J; (...); Castel, V
Review. 10.1055/s-0036-1572362. 2015
Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
Di Cataldo, A; (...); Canete, A
Article. 10.1007/s12094-016-1505-1. 2017
Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; (...); Castel V
Article. 10.1007/s00432-011-0997-x. 2011
miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
Berlanga P; (...); Font de Mora J
Article. 10.1016/j.molonc.2016.04.004. 2016
MORTALITY FROM SECOND TUMORS AMONG LONG-TERM SURVIVORS OF RETINOBLASTOMA: AN 87 CASE SERIES REPORT
Balaguer, Julia; (...); Castel, Victoria
Article. 2009
MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
Olivera, GG; (...); Herrero, MJ
Article. 10.3390/ijms21082714. 2020
Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration
Berbegall AP; (...); Noguera R
Article. 10.1016/j.neo.2014.05.012. 2014
NEUROBLASTOMA INCIDENCE AND SURVIVAL IN COMUNITAT VALENCIANA
Canete, Adela; (...); Castel, Victoria
Article. 2010
Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas
Ribelles, AJ; (...); Canete, A
Article. 10.3390/jpm11040268. 2021
Paediatric tumour boards in Spain: a national survey
Berlanga, P; (...); Canete, A
Article. 10.1007/s12094-015-1466-9. 2016
PHARMACOGENETIC VARIANTS ASSOCIATED WITH TREATMENT RESPONSE IN NEUROBLASTOMA
Olivera, G; (...); Alino, SF
Meeting Abstract. 2018
Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
Olivera, Gladys; (...); Alino, Salvador F.
Review. 10.20517/cdr.2018.25. 2019
Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
Olivera, GG; (...); Herrero, MJ
Review. 10.3390/ijms22189815. 2021
Plasma Metabolomic Profiling Differentiates High- and Low-Risk Neuroblastoma Patients
Quintas, G; (...); Segura, V
Meeting Abstract. 2018
Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience
Berlanga, Pablo; (...); Castel, Victoria
Article. 10.1097/MPH.0000000000000546. 2016
Precision medicine in Ewing sarcoma: a translational point of view.
Gargallo P; (...); Cañete A
Review. 10.1007/s12094-020-02298-7. 2020
Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience
Berlanga, Pablo; (...); Castel, Victoria
Article. 10.1097/MPH.0000000000000270. 2015
Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
Juan Ribelles A; (...); Castel V
Correction. 10.1038/s41598-020-58428-2. 2020
QUANTITATIVE APPROACH TO ASSIST NEUROBLASTOMA ASSESSMENT BY MEASURING I-123 mIBG UPTAKE IN SCINTIGRAPHIC IMAGES
Martinez-Diaz, Rafael; (...); Peris-Fajarnes, Guillermo
Article. 10.5566/ias.1219. 2015
Retinoblastoma and mosaic 13q deletion: a case report
Gargallo P; (...); Canete, A
Article. 10.1186/s40942-021-00321-9. 2021
Review: Ewing Sarcoma Predisposition.
Gargallo P; (...); Cañete A
Article. 10.1007/s12253-019-00765-3. 2019
Solid ovarian tumours in childhood: a 35-year review in a single institution
del Mar Andres, Maria; (...); Castel, Victoria
Article. 10.1007/s12094-010-0505-9. 2010
Subtelomeric analysis of pediatric astrocytoma: subchromosomal instability is a distinctive feature of pleomorphic xanthoastrocytoma.
Grau E; (...); Castel V
Article. 10.1007/s11060-008-9763-6. 2009
Success of the HR-NBL/SIOPEN local control trial strategy in high risk neuroblastoma patients undergoing high dose therapy with peripheral stem cell transplantation
Ladenstein, R; (...); Botterberg, T
Meeting Abstract. 2018
Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project
Juan Ribelles A; (...); Ladenstein, R
Article. 10.1007/s12094-017-1820-1. 2018
Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor.
Hämmerle B; (...); Font de Mora J
Article. 10.1371/journal.pone.0076761. 2013
TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients
Yáñez Y; (...); Castel V
Article. 10.1007/s00432-015-2054-7. 2016
TIAM1 variants improve clinical outcome in neuroblastoma
Sanmartin, E; (...); Font de Mora J
Article. 10.18632/oncotarget.16787. 2017
Two independent epigenetic biomarkers predict survival in neuroblastoma.
Yáñez Y; (...); Castel V
Article. 10.1186/s13148-015-0054-8. 2015